

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA

ABN 84 152 713 098

FINANCIAL REPORT

for the year ended 30 June 2022

CONTENTS

	Page
1. Directors' Report	3
2. Auditor's Independence Declaration	8
3. Financial Report	
Statement of Profit or Loss and Other Comprehensive Income	9
Statement of Changes in Equity	10
Statement of Financial Position	11
Statement of Cash Flows	12
Notes to the Financial Statements	13
4. Directors' Declaration	19
5. Independent Auditor's Report to the Members	20

This Financial Report covers National Stem Cell Foundation of Australia ('the Company') as an individual entity. National Stem Cell Foundation of Australia is a Company limited by guarantee, incorporated and domiciled in Australia.

The Company's registered office and principal place of business is:

Suite 5
242 Hawthorn Road
Caulfield Victoria 3162

A description of the nature of the Company's operations and its principal activities is included in the Directors' Report on pages 3 to 7 which is not part of this Financial Report.

The Financial Report was authorised for issue by the directors on 1 September 2022. The directors have the power to amend and reissue the Financial Report.

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

The directors present their report together with the Financial Report of National Stem Cell Foundation of Australia for the year ended 30 June 2022 and the Auditor's Report thereon.

Directors

The directors of the Company at any time during or since the end of the year are:

<i>Name</i>	<i>Age</i>	<i>Period of directorship, special responsibilities, experience, other current directorships and former directorships in the last three years. Note: FARM is Finance, Audit and Risk Management Committee and SE is Science and Ethics Committee</i>
Dr Graeme Blackman AO, PhD, BSc (Hons), BD, MTheol, FTSE, FRACI, FAICD, FloD (Non-Executive Director, Chairman, Member of FARM Committee)	76	Independent non-executive director and Chairman of the Company, appointed 17 August 2011. Dr Blackman is a former Professor of Pharmaceutical Chemistry at the Victorian College of Pharmacy and a former director of IDT Australia Ltd, an Australian Securities Exchange (ASX) listed public company operating in the pharmaceutical industry. He was a director of the Australian Stem Cell Centre. He has been a member of various Commonwealth and State advisory committees and working groups in pharmaceuticals and biotechnology, including the Australian Biotechnology Advisory Council, the Pharmaceutical Industry Working Group and the Pharmaceutical Industry Strategy Group. He chaired the Australian Government's Pharmaceuticals Industry Action Agenda, which developed a policy framework for the industry over a ten year period.
Mr Stuart Gooley BComm (Melb), FCA, FCPA (Non-Executive Director, Chairman of FARM Committee)	77	Independent non-executive director and Chairman of the Finance, Audit and Risk Management Sub-committees appointed 17 August 2011. Mr Gooley had a 42 year period in the accounting profession with Arthur Andersen and Ernst & Young, and retired from public practice in 2008. During his career he was the Australian head of Andersen's Accounting and Audit practice and the Asia Pacific Risk Management Practice Director. Mr Gooley was the Victorian State President of CPA Australia in 1994, and served on the Australian Auditing and Assurance Standards Board and the International Auditing Practices Committee. Outside of the accounting profession he has served on the board of two educational institutions, and is currently a director of Lahaina Holdings Pty Ltd, Tai Tam Investments Pty Ltd, Wilson Transformer Company and Mornington Yacht Club. He was a director of the Australian Stem Cell Centre.
Professor Caroline Gargett B Appl Sci, M Appl Sci, PhD (Non-Executive Director, Chairman of SE Committee)	70	Independent non-executive director appointed 15 December 2014 and Chair of the Science and Ethics Committee since August 14, 2018. Professor Gargett is currently a National Health & Medical Research Council (NHMRC) Leadership Fellow, Women's Health Theme Leader at the Ritchie Centre, Hudson Institute of Medical Research and heads the Endometrial Stem Cell Biology Group. She leads collaborative research with Flinders and Warwick Universities investigating the use of endometrial mesenchymal stem cells for regenerative medicine application in urogynaecology and with University of Queensland on genomics of endometrial stem/progenitor cells in endometriosis. Professor Gargett has served as President of the Australasian Society for Stem Cell Research (2013-2014) and co-led the successful bid that brought the International Society for Stem Cell Research conference to Melbourne in 2018. She is currently a Board Member of Stem Cells Incorporated and Scientific Advisory Board member of the Centre for Commercialisation in Regenerative Medicine Australia.
Mr David Collins MEng, MBA, CA, GAICD (Non-Executive Director, Member of FARM Committee)	57	Independent non-executive director and member of the Finance, Audit and Risk Management Sub-committee appointed 16 December 2011. Mr Collins is a partner in an accountancy and consultancy firm and has previously held senior executive positions in companies in Europe and the UK within the media industry. Mr Collins was Chief Executive Officer of the Australian Stem Cell Centre from September 2009 until November 2011.

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

Associate Professor Ngaire Elwood PhD, BSc(Hons), MAICD (Non-Executive Director, Member of SE Committee)	57	<p>Independent non-executive director appointed 30 April 2018. Assoc Professor Ngaire Elwood is the Director of the BMDI Cord Blood Bank and Head of the Cord Blood Stem Cell Research Laboratory at the Murdoch Childrens Research Institute in Melbourne. Assoc Professor Elwood has extensive experience in the field of stem cells, cellular therapy, cancer and cord blood. Her current research is aimed at understanding cord blood stem cell biology, improving cord blood transplant outcome and exploring the use of cord blood for regenerative therapies. Assoc Professor Elwood serves as Vice President of the international Board of Directors for the Foundation for the Accreditation of Cellular Therapy (FACT) and sits on various executive committees within FACT. She was the Regional Vice President (2018–2020) for the Australia New Zealand Region of the International Society for Cellular Therapy (ISCT) and is Chair of the AusCord network of public cord blood banks.</p>
Professor Emeritus James A. Angus AO, FAA, FAHMS (Hon) BSc, PhD (Non-Executive Director, Member of SE Committee)	73	<p>Independent non-executive director appointed 12 August 2020. Professor James Angus is a Biomedical Pharmacologist. Professor Angus was Dean of The Faculty of Medicine, Dentistry and Health Sciences at The University of Melbourne from 2003 to 2013, a period of major growth and development of the Parkville health and biomedical research precinct. He has been President of the Academic Board and a member of Council of the University. He is currently, Chair of The Campus Council at the Melbourne Children's Campus integrating The Royal Children's Hospital, the Murdoch Children's Research Institute Department of Paediatrics The University of Melbourne and The RCH Foundation. He is Chair of the Australian Advisory Board on The Medicinal Use of Cannabis, a Director of The Jack Brockhoff Foundation, a Director of Science Australia Gender Equity Ltd and a Director of The Royal Children's Hospital Foundation. In November 2021 he was appointed the 15th Lieutenant- Governor of Victoria.</p>
Professor Megan Munsie PhD, BAppSc, MRepSc (Non-Executive Director, Member of SE Committee)	55	<p>Independent non-executive director appointed 25 May 2020. Professor Megan Munsie is an internationally recognised biologist who has made a significant contribution to policy development and community engagement in stem cell science and regenerative medicine at a domestic and global level. She is Professor of Emerging Technology (Stem Cells) at the Melbourne Medical School and Group Leader of Stem Cell Ethics & Policy at the Murdoch Children's Research Institute. She also leads the preparedness research theme for the international Novo Nordisk Foundation Centre for Stem Cell Medicine. Professor Munsie is the Vice President of the Australasian Society for Stem Cell Research serves on advisory committees to national and international scientific organisations including the Ethics and Public Policy committees for the International Society for Stem Cell Research.</p>
Mr Graeme Mehegan BBus(Acc), FCPA, FCIS, MFIA (Company Secretary, Member of FARM and SE Committee)	67	<p>Mr Graeme Mehegan was appointed Company Secretary 8 November 2011 and appointed General Manager on 1 March 2019. Mr Mehegan was Chief Financial Officer for the Australian Stem Cell Centre from August 2009 until November 2011. He was Chief Financial and Operations Officer and Company Secretary for Pioneer Electronics Australia from January 2001 until March 2008 and prior to that held senior roles in the book publishing industry over twenty years including the positions of Director, Company Secretary, Business Manager and Financial Controller with Random House Australia and Financial Controller and Company Secretary with Pitman Publishing Australia.</p>

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

Principal activities

The National Stem Cell Foundation of Australia is an Australian Tax Office (ATO) registered Health Promotion Charity dedicated to promoting the study and responsible use of stem cells to reduce the burden of disease.

The Foundation's priorities are:

- Supporting research that pursues cures for not yet treatable diseases
- Building a community of people with a shared interest in stem cell science
- Providing the Australian public with objective, reliable information on both the potential and risks of stem cell medicine.

Short-term objectives

The Company funds a broad program of activities that supports Stem Cell Science in Australia. During the year ended 30 June 2022 \$925,763 (2021: \$515,905) was contributed towards health promotion activities and since the formation of the Foundation contributions now total \$3,494,180.

The Company is currently taking steps to significantly increase both its fundraising income and expenditure on activities to promote stem cell science in years to come.

Long-term Objectives

The Company's long-term objectives are to:

- Pursue the cures for not yet treatable diseases and illnesses using stem cell technology and regenerative medicine techniques by supporting research activities in these areas.
- Provide resources to develop objective information and to educate and inform the Australian public on stem cell technology and regenerative medicine including its risks, achievements, benefits and overall technical progress.

Strategy for achieving short and long-term objectives

To achieve these objectives, the Company will draw heavily on the experience of its Board of Directors and Management who (as a group) have considerable and varied experience in medical research, business management and finance.

The Board will seek to appoint experts in various fields where specialised expertise and scientific advice is required including:

- Investment strategy
- Website development and marketing
- Promotion and public relations

Given the nature of its activities and the Health Promotion Charity status of the Company, the Board has successfully obtained some services on a pro-bono basis but in other cases has found it necessary to enlist external paid consultants.

The Foundation provided philanthropic financial support for the following health promotion activities in support of Australian stem cell science:-

- **The ongoing development of its Matched Funding Program** aimed at providing \$6 million in direct funding for stem cell based research projects over ten years. There are now ten of these projects in place with the Company providing \$779,858 this financial year as part of the program. Research covered by the funding includes type 1 Diabetes, recovery from heart trauma, repairing damage to large bones, developing a new treatment for MCDS which is a rare autosomal dominant disorder of bone and cartilage, retinal gene therapy and a new treatment for vitiligo and melanoma. The Company's website (stemcellfoundation.net.au) provides more details on these projects and how individuals and organizations can provide funding for these as well as donating directly to the Foundation.
- **Continued with its Awarding** of the annual NSCFA Metcalf Prizes for mid-career researchers working in stem cell research in Australia with the successful applicants being Assoc Prof Siok Tey and Dr Pengyi Yang. These two researchers join the impressive list of Metcalf winners, the details of which are covered on the next page.

The Company normally provides travel grants for students and early career researchers to attend the Australasian Society of Stem Cell Research conference however this year's conference was cancelled due to COVID-19.

Additionally during the year the Foundation published 7 newsletters.

During the year the Foundation published a new guidebook – ***What you need to know about stem cell therapies*** – for people contemplating stem cell-based treatments or clinical trials. This included information on what proven stem cell therapies are available, what's at risk from trying an unproven, experimental treatment, and what do patients and their families need to know?

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

Investment Performance

The majority of the Company's investments are placed with a number of fund managers who specialise in investment in domestic equities, international equities and foreign credit. The economic impact arising from COVID-19 and recent international political issues has resulted in a high level of volatility in the profitability of these investments over the past three years. It has manifested itself in a reduction in income from investments and losses arising from the revaluation of assets to fair value in the year ended 30 June 2022 compared to an increase in income from investments and significant profits arising from the revaluation of assets to fair value for the year ended 30 June 2021.

The Metcalf Prize

The Metcalf Prizes for Stem Cell Research recognise and honour the exceptional contribution made to stem cell research by the late Professor Donald Metcalf. Over his 50-year career, Don helped transform cancer treatment and transplantation medicine, and paved the way for potential stem cell therapy in the treatment of many other conditions.

The Metcalf Prizes for Stem Cell Research are open to mid-career researchers who are five to 10 years past their PhD or MD (research-based) and working in stem cell research in Australia. They could be working in medicine or agriculture, government or academia, and have a primary focus on stem cells.

The winners are chosen for their scientific excellence, proven leadership ability and the potential to have a continuing influence on stem cell research in Australia.

Past Metcalf Prize winners include:

- Brisbane clinical haematologist Associate Professor Siok Tey
- Canberra computer specialist Pengyi Yang
- Molecular biologist now based at the Peter MacCallum Cancer Centre Dr Melanie Eckersley-Maslin.
- Brisbane clinical haematologist Associate Professor Steven Lane
- Mammary gland expert Felicity Davis who holds a joint appointment between the University of New South Wales and Aarhus University in Denmark.
- Brisbane based bioengineer James Hudson
- Newcastle leukaemia researcher Heather Lee,
- Melbourne heart development researcher Enzo Porrello,
- Melbourne haematologist Mark Dawson,
- Brisbane computational biologist Jessica Mar,
- Sydney heart clinician and researcher James Chong,
- Melbourne immunologist Tracy Heng,
- Bioinformatician Christine Wells who is Professor of Stem Cell Systems and Director of the University of Melbourne Centre for Stem Cell Systems.
- Perth geneticist Ryan Lister,
- Tasmanian neural stem cell researcher Kaylene Young, and
- Reprogramming legend Jose Polo who is Director Adelaide Centre for Epigenetics at the University of Adelaide.

Directors' meetings

The number of directors' meetings (including meetings of committees of directors) and number of meetings attended by each of the directors of the Company during the year were:

	Directors' Meetings		Finance, Audit and Risk Management Sub-Committee Meetings		Science and Ethics Sub-Committee Meetings	
	Attended (ii)	Held (i)	Attended (ii)	Held (i)	Attended (ii)	Held (i)
Dr G Blackman	4	4	4	4		
Mr S Gooley	4	4	4	4		
Mr D Collins	3	4	4	4		
Prof C Gargett	4	4			6	6
Associate Professor N Elwood	4	4			6	6
Professor J Angus	4	4			6	6
Professor M Munsie	4	4			6	6

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

- (i) Represents the number of meetings held during the time that the director held office or was a member of the committee during the year.
- (ii) Director either attended or their duly appointed alternate director attended on their behalf.

The Finance, Audit and Risk Management Sub-committee is chaired by Mr S Gooley and its role is to review the implementation of the risk management processes, financial reporting, internal control and management of financial risks, the audit process, and the Company's process for monitoring compliance with laws and regulations. The sub-committee is also responsible for monitoring and utilising the services of an independent consultant to provide expertise and advice on investment strategy and performance.

The Foundation's Science and Ethics Committee is chaired by Professor Caroline Gargett. It is responsible for providing the Board with information and guidance on the current state of stem cell science, research activities in the area, ethical issues that arise and how they have been dealt with by regulatory bodies or governments. The Committee also oversees the Foundation's major research support activity, the selection of recipients of two Metcalf prizes annually for mid-career researchers in stem cell science and is responsible for replying to enquiries from members of the public seeking information about stem cell treatments. The Committee is responsible for managing the evaluation process of projects applying for funding under the new Matched Funding Program including calling for applications, soliciting reviews from experts in the various fields and preparing final recommendations to the Board for consideration.

Contribution in Winding Up

The Company is incorporated under the Corporations Act 2001 and is a company limited by guarantee. If the Company is wound up the constitution states that each member is required to contribute a maximum of \$100 each towards meeting any outstanding obligations of the entity. At 30 June 2022, the total amount that members of the Company are liable to contribute if the Company is wound up is \$700.

State of Affairs

Other than the matters described above in Review of Operations, there have been no other significant changes in the state of affairs of the Company during the financial year.

Events Subsequent to Balance Date

The impact of the COVID-19 pandemic is ongoing. It is difficult to estimate the potential impact, positive or negative, after the reporting date. The situation is dependent on measures imposed by the Australian Government and other countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.

Other than the above, no matters or circumstances have arisen since the end of the financial year that significantly affected or may significantly affect the operations of the Company, the results of those operations or the state of affairs of the Company in subsequent financial years, not otherwise disclosed in this report.

Auditors' independence declaration

A copy of the auditors' independence declaration as required under section 60-40 of the *Australian Charities and Not-for-profits Commission Act 2012* is set out on page 8.

Dated at Melbourne this 1st day of September 2022.

Signed in accordance with a resolution of the directors.



Dr Graeme Blackman AO
(Chairman)

Auditor's Independence Declaration

To National Stem Cell Foundation of Australia,


In accordance with the requirements of section 60-40 of the *Australian Charities and Not-for-Profits Commission Act 2012*, as lead auditor for the audit of National Stem Cell Foundation of Australia for the year ended 30 June 2022, we declare that, to the best of our knowledge and belief, there have been:

- i) No contraventions of the independence requirements of the *Australian Charities and Not-for-Profits Commission Act 2012* in relation to the audit, and;
- ii) No contraventions of any applicable code of professional conduct in relation to the audit.

Dated at Frankston on the 1st of September 2022



SHEPARD WEBSTER & O'NEILL AUDIT PTY LTD
Certified Practising Accountant
Authorised Audit Company No 415478
31 Beach Street Frankston 3199, PO Box 309 Frankston Victoria 3199
Telephone (03) 9781 2633 – Fax (03) 9781 3073
Email – szeffalusy@shepard.com.au



DAVID A SZEFFALUSY
DIRECTOR

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME for the year ended 30 June 2022

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA ABN 84 152 713 098

Statement of profit or loss and other comprehensive income for the year ended 30 June 2022	Note	Year Ended 30 June 2022	Year Ended 30 June 2021
		\$	\$
Income from Operations	2	699,374	851,040
Administrative costs	3	(138,091)	(127,856)
Promoting stem cell science and projects	3	(925,763)	(515,905)
Gain/(Loss) on investments		(582,728)	477,649
Profit / (Loss) before income tax		(947,208)	684,928
Income tax expense		-	-
Profit / (Loss) for the year		(947,208)	684,928
Other comprehensive income for the year		-	-
Total comprehensive income for the year		(947,208)	684,928

This Statement of profit or loss and other comprehensive income is to be read in conjunction with the Notes to the Financial Statements set out on pages 13 to 18.

STATEMENT OF CHANGES IN EQUITY

for the year ended 30 June 2022

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA ABN 84 152 713 098

For the year ended 30 June 2022	Retained Earnings	Total Equity
	\$	\$
Total equity at the beginning of the financial year	5,247,236	5,247,236
Profit / (Loss) for the year	(947,208)	(947,208)
Total comprehensive profit for the year	(947,208)	(947,208)
Total equity at the end of the financial year	4,300,028	4,300,028

For the year ended 30 June 2021	Retained Earnings	Total Equity
	\$	\$
Total equity at the beginning of the financial year	4,562,308	4,562,308
Loss for the year	684,928	684,928
Total comprehensive loss for the year	684,928	684,928
Total equity at the end of the financial year	5,247,236	5,247,236

This Statement of changes in equity is to be read in conjunction with the Notes to the Financial Statements set out on pages 13 to 18.

Statement of financial position

as at 30 June 2022

	Note	2022	2021
		\$	\$
Current assets			
Cash and cash equivalents	4	7,705	489,842
Trade and other receivables	5	244,270	282,339
Other financial assets	6	4,120,635	4,631,535
Total current assets		4,372,610	5,403,716
Total assets		4,372,610	5,403,716
Current liabilities			
Trade and other payables	7	72,582	156,480
Total current liabilities		72,582	156,480
Total liabilities		72,582	156,480
Net assets		4,300,028	5,247,236
Equity			
Retained earnings	8	4,300,028	5,247,236
Total equity		4,300,028	5,247,236

This Statement of financial position is to be read in conjunction with the Notes to the Financial Statements set out on pages 13 to 18.

STATEMENT OF CASH FLOWS

for the year ended 30 June 2022

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

Statement of cash flows

for the year ended 30 June 2022

Note

**Year Ended
30 June 2022****Year Ended
30 June 2021**

		\$	\$
Cash flows from operating activities			
Profit / (loss) after related income tax		(947,208)	684,928
Change in assets and liabilities:			
Gain / (Loss) on Investments		582,728	(477,649)
Trade and other receivables		38,069	(189,291)
Trade and other payables		(83,898)	17,435
Net cash inflow / (outflow) from operating activities		(410,308)	35,423
Cash flows from investing activities			
Proceeds from sales of investments		958,171	800,000
Payments for new investments		(1,030,000)	(1,050,000)
Net cash inflow / (outflow) from investing activities		(71,829)	(250,000)
Net decrease in cash held		(482,137)	(214,577)
Cash and cash equivalents at the beginning of the year		489,842	704,419
Cash and cash equivalents at the end of the year	4	7,705	489,842

This Statement of cash flows is to be read in conjunction with the Notes to the Financial Statements set out on pages 13 to 18.

1 Significant accounting policies

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

a) New or amended Accounting Standards and Interpretations adopted

The company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the company.

The following Accounting Standards and Interpretations are most relevant to the company:

Conceptual Framework for Financial Reporting (Conceptual Framework)

The company has adopted the revised Conceptual Framework from 1 July 2021. The Conceptual Framework contains new definition and recognition criteria as well as new guidance on measurement that affects several Accounting Standards, but it has not had a material impact on the company's financial statements.

AASB 1060 General Purpose Financial Statements - Simplified Disclosures for For-Profit and Not-for-Profit Tier 2 Entities

The company has adopted AASB 1060 from 1 July 2021. The standard provides a new Tier 2 reporting framework with simplified disclosures that are based on the requirements of IFRS for SMEs. As a result, there is increased disclosure in these financial statements for key management personnel and related parties.

Basis of preparation

These general purpose financial statements have been prepared in accordance with the Australian Accounting Standards - Simplified Disclosures issued by the Australian Accounting Standards Board ('AASB'), the Australian Charities and Not-for-profits Commission Act 2012 and Victorian legislation the Fundraising Act 1998 and associated regulations and the Corporations Act 2001, as appropriate for not-for-profit oriented entities.

Historical cost convention

The financial statements have been prepared under the historical cost convention, except for, where applicable, the revaluation of financial assets and liabilities at fair value through profit or loss, financial assets at fair value through other comprehensive income, investment properties, certain classes of property, plant and equipment and derivative financial instruments.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 1(k).

b) Accounting policies for financial instruments under AASB 9Classification and subsequent measurement of financial assets

Except for those trade receivables that do not contain a significant financing component and are measured at the transaction price, all financial assets are initially measured at fair value adjusted for transaction costs (where applicable).

For the purpose of subsequent measurement, financial assets other than those designated and effective as hedging instruments are classified into the following categories upon initial recognition:

- amortised cost
- fair value through profit or loss (FVPL)
- equity instruments at fair value through other comprehensive income (FVOCI)

Classifications are determined by both:

- The entities business model for managing the financial asset
- The contractual cash flow characteristics of the financial assets

All income relating to financial assets that are recognised in profit or loss are presented within income from operations.

All expenses relating to financial assets, if any, that are recognised in profit or loss are presented within finance costs, except for impairment of trade receivables, which is presented within other expenses. There were no expenses relating to financial assets during the year.

Subsequent measurement of financial assetsFinancial assets at amortised cost

Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL):

- they are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows
- the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding

After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables fall into this category of financial instruments that were previously classified as held-to-maturity under AASB 139.

Financial assets at fair value through profit or loss (FVPL)

Financial assets that are held within a different business model other than 'hold to collect' or 'hold to collect and sell' are categorised at fair value through profit and loss.

Further, irrespective of business model financial assets whose contractual cash flows are not solely payments of principal and interest are accounted for at FVPL.

Classification and measurement of financial liabilities

The Company's financial liabilities include trade payables.

Financial liabilities are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the Company designated a financial liability at fair value through profit or loss.

Subsequently, financial liabilities are measured at amortised cost using the effective interest method.

c) Foreign currency

Functional and presentation currency

Items included in the financial statements of the Company are measured and presented in Australian dollars.

Transactions and balances

Foreign currency transactions are initially translated into Australian currency using the exchange rates prevailing at the date of each transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement.

d) Income recognition

Revenue is measured at the fair value of the consideration received or receivable after taking into account any trade discounts and volume rebates allowed. For this purpose, deferred consideration is not discounted to present values when recognising revenue.

Operating Grants, Donations and Bequests

When the Company receives operating grant revenue, donations or bequests, it assesses whether the contract is enforceable and has sufficiently specific performance obligations in accordance with AASB 15.

When both these conditions are satisfied, the Company:

- i. identifies each performance obligation relating to the grant - recognises a contract liability for its obligations under the agreement
- ii. recognises revenue as it satisfies its performance obligations.

Where the contract is not enforceable or does not have sufficiently specific performance obligations, the Company:

- i. recognises the asset received in accordance with the recognition requirements of other applicable accounting standards (e.g. AASB 9, AASB 16, AASB 116 and AASB 138)
- ii. recognises related amounts (being contributions by owners, lease liability, financial instruments, provisions, revenue or contract liability arising from a contract with a customer)
- iii. recognises income immediately in profit or loss as the difference between the initial carrying amount of the asset and the related amount.

If a contract liability is recognised as a related amount above, the Company recognises income in profit or loss when or as it satisfies its obligations under the contract.

Donation Income

Donations (both general and matched funding) are only brought to account when the funds are received into the bank account, that is, when control over the funds is established, or the right to receive the funds has been recognised.

Other revenue:

Other revenue is recognised when it is received or when the right to receive payment is established.

The Company's accounting policy is to not recognise the benefit of any volunteer services.

Franking credits:

Franking credits are recognised when the right to receive the revenue has been established and can be reliably measured.

e) Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the Company's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the Company's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

f) Matched Funding Program

The Company has executed research funding agreements with other entities to provide a specified funding amount conditional upon the Company funding amount being matched dollar for dollar by an approved donor.

The Company recognises the donation income when the donation is received and also at that time recognises the liability to pay the combined research funding amount.

g) Income tax

The Company has received a private ruling from the Australian Taxation Office (ATO) to receive exemption from income tax pursuant to the provisions of section 50-5 of the *Income Tax Assessment Act 1997*. The Company currently considers that it will continue to be exempt under the self assessment system applying under section 50-5 of the *Income Tax Assessment Act 1997*.

h) Trade and other payables

These amounts represent liabilities for goods and services provided to the Company prior to the end of the financial period and which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition.

i) Goods and services tax (GST)

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the amount of GST incurred is not recoverable from the ATO. In this case it is recognised as part of the cost of acquisition of the asset or as part of an item of expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included as a current asset or liability in the balance sheet.

The GST components of cash flows arising from investing and financing activities which are recoverable from, or payable to, the ATO are classified as operating cash flow.

j) Cash and cash equivalents

For cash flow statement presentation purposes, cash and cash equivalents includes deposits at call with financial institutions and other highly liquid investments with short periods to maturity that are readily convertible to cash on hand and are subject to an insignificant risk of changes in value.

k) Critical accounting estimates and judgements

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements.

Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Coronavirus (COVID-19) pandemic

Judgement has been exercised in considering the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the company based on known information. This consideration extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the company operates. Other than as addressed in specific notes, there does not currently appear to be either any significant impact upon the financial statements or any significant uncertainties with respect to events or conditions which may impact the company unfavourably as at the reporting date or subsequently as a result of the Coronavirus (COVID-19) pandemic.

Estimation of useful lives of assets

The company determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

Impairment of non-financial assets other than goodwill and other indefinite life intangible assets

The company assesses impairment of non-financial assets other than goodwill and other indefinite life intangible assets at each reporting date by evaluating conditions specific to the company and to the particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions.

Employee benefits provision

As discussed in note 1, the liability for employee benefits expected to be settled more than 12 months from the reporting date are recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

	Note	Year Ended 30 June 2022	Year Ended 30 June 2021
		\$	\$
2 Income from Operations			
Donations and bequests		386,081	355,928
Income from investments		312,606	483,563
Interest Income		43	839
Other income		644	10,710
Total revenue		699,374	851,040
3 Expenses			
Expenditure classified by function			
Administrative Expenses			
- Salaries and on-costs		77,000	67,500
- Directors expenses		-	714
- Audit Fees		5,500	4,500
- Professional fees		40,512	40,512
- Insurance		5,310	4,603
- Other administration expenses		9,769	10,027
Total Administrative Expenses		138,091	127,856
Expenses incurred in promoting Stem Cell Science including projects		925,763	515,905
Total expenditure		1,063,854	643,761
4 Cash and cash equivalents			
Cash at bank and on hand		7,705	489,842
Total cash and cash equivalents		7,705	489,842
The above figures are reconciled to cash at the end of the financial period as shown in the Statement of Cash Flows.			
5 Trade and other receivables			
Other receivables		242,884	280,953
Prepayments		1,386	1,386
Total receivables		244,270	282,339

	Note	Year Ended 30 June 2022	Year Ended 30 June 2021
		\$	\$
6 Other financial assets			
Financial assets measured at fair value through profit and loss			
- Investments held in managed funds		4,120,635	4,631,535
Total investments		4,120,635	4,631,535
7 Trade and other payables			
Trade payables		72,582	156,480
Total trade and other payables		72,582	156,480
8 Equity			
Retained profits		4,300,028	5,247,236
Total equity		4,300,028	5,247,236
9 Related party disclosures			
Directors and other key management personnel			
Apart from the amounts and issues disclosed in this note, there were no other transactions or balances with related parties during or at the end of the financial period.			
Key management personnel compensation			
Total key management personnel remuneration		77,000	67,500
Controlling entities			
From incorporation of the Company in August 2011 the sole members of the company are the directors of the company.			
10 Remuneration of Auditors			
Audit of the financial statements		5,500	4,500
Other Services		-	-
		5,500	4,500
11 Lease commitments			
The Company has no future operating lease payments.			

12 Members' guarantee

The Company was incorporated on 17 August 2011 as a Company limited by guarantee and not having a share capital. If the Company is wound up, the Constitution states that current Members (of which there are seven), and any persons whom were Members within the last 12 months immediately prior, are required to contribute an amount determined by the Company, but not exceeding \$100, to meet the outstanding obligations of the Company, if required.

13 Events occurring after the reporting date

The impact of the COVID-19 pandemic is ongoing. It is difficult to estimate the potential impact, positive or negative, after the reporting date. The situation is dependent on measures imposed by the Australian Government and other countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.

Aside from the above, there have been no further significant events occurring after the reporting period which may affect the operations of the Company, not otherwise disclosed in this report.

14 Contingent liabilities

The Company has contracted to provide funding for research projects over a five year period. If various conditions are met, the company is contracted to pay \$303,287 in the year ending 30 June 2023 and a further \$600,000 over the following three years.

Directors' Declaration

In the directors' opinion:

- (a) the Financial Statements, comprising the Statement of Profit or Loss and Other Comprehensive Income, Statement of Financial Position, Statement of Cash Flows and Statement of Changes in Equity, and accompanying notes, as set out on pages 10 to 18 are in accordance with the *Australian Charities and Not-for-profits Commission Act 2012*, and:
 - (i) comply with Australian Accounting Standards – Reduced Disclosure Requirements and the *Australian Charities and Not-for-profits Commission Regulations 2013*; and
 - (ii) give a true and fair view of the Company's financial position as at 30 June 2022 and of its performance for the financial period ended on that date; and
- (b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.



Dr Graeme Blackman AO

Chairman

Melbourne

1 September 2022

**National Stem Cell Foundation of Australia
Independent Auditor's Report to the Members
ABN 84 152 713 098**

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of National Stem Cell Foundation of Australia, which comprises the Statement of Financial Position as at 30 June 2022, Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the Directors' declaration.

In our opinion, the accompanying financial report of National Stem Cell Foundation of Australia has been prepared in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (i) giving a true and fair view of the Company's financial position as at 30 June 2022 and of its performance for the year then ended; and
- (ii) complying with Australian Accounting Standards – Simplified Disclosures Requirements and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of our report. We are independent of the Company in accordance with the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110: Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Financial Report and Auditor's Report Thereon

The Directors of the Company are responsible for the other information. The other information comprises the information included in the Company's annual report for the year ended 30 June 2022, but does not include the financial report and our auditor's report thereon. Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**National Stem Cell Foundation of Australia
 Independent Auditor's Report to the Members (continued)
 ABN 84 152 713 098**

Responsibilities of the Directors for the Financial Report

The Directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards – Simplified Disclosures Requirements and the *Australian Charities and Not-for-profits Commission Act 2012* and for such internal control as the Directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

The Directors of the Company are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.
- Conclude on the appropriateness of the Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

**National Stem Cell Foundation of Australia
Independent Auditor's Report to the Members (continued)
ABN 84 152 713 098**

We communicate with the Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Dated at Frankston on the 1st day of September 2022



SHEPARD WEBSTER & O'NEILL AUDIT PTY LTD
Certified Practising Accountant
Authorised Audit Company No 415478
31 Beach Street Frankston 3199, PO Box 300 Frankston Victoria 3199
Telephone (03) 9781 2633 – Fax (03) 9781 3073
Email – szepefalusy@shepard.com.au



DAVID A SZEPEFALUSY
DIRECTOR